Only 6.9% of people with Lynch syndrome in Germany use aspirin for cancer prevention, despite strong evidence of its effectiveness, according to a study published in The Lancet Gastroenterology & Hepatology.
A survey of 539 individuals with Lynch syndrome in Germany revealed that just 6.9% used acetylsalicylic acid (aspirin) specifically for cancer prevention, while 10.4% were taking it overall. The findings, from the LYNX study, highlight a significant gap between scientific evidence and clinical practice, despite aspirin’s proven role in reducing colorectal cancer risk in this high-risk group.
Study Reveals Sharp Disconnection Between Evidence and Practice
The LYNX study, conducted between December 2025 and February 2026, found that 97% of participants were aware of screening recommendations for Lynch syndrome, with nearly all undergoing regular colonoscopies. However, only 10.4% reported current aspirin use, and 6.9% used it for cancer prevention. Dr. Robert Hüneburg, a senior physician at Medical Clinic I at the UKB, noted that future studies must show whether the new findings on lower dosages will contribute to Acetylsalicylic acid being used more frequently for cancer prevention.
The research, authored by Anne-Sophie Layritz, Nicola Reents, Katrin van Beekum, Prof. Jacob Nattermann, and Robert Hüneburg, underscores the need for better communication between clinicians and patients. Hüneburg highlighted the importance of timely, transparent, and organized patient communication, along with a personalized evaluation of advantages and potential risks. The research involved experts from University Hospital Bonn, the University of Bonn, the Bonn Integrated Oncology Center, and the SemiColon organization, focusing on patient-focused research.
Low Dose Aspirin Shows Promise, But Adoption Lags
International studies, including the CAPP2 trial, have demonstrated that aspirin can reduce colorectal cancer risk in Lynch syndrome patients. The newer CaPP3 study suggests that a lower daily dose of 100 mg may offer similar protection with fewer side effects, including bleeding. However, the LYNX survey—conducted before CaPP3’s publication—reflects the previous use of Acetylsalicylic acid based on the scientific evidence available at that time, with participants primarily informed by the higher-dose CAPP2 findings.
Since the statistical criteria for formal equivalence between the two studies were not met in all analyses, the results should still be interpreted with some caution,
Hüneburg cautioned. Nevertheless, the CaPP3 results suggest that 100 mg daily could be a practical and better-tolerated option for many patients,
he added. The study’s authors argue that updated guidelines and patient education could bridge the implementation gap.
Barriers to Aspirin Use Include Concerns and Uncertainty
The main reasons cited for low aspirin adherence were a lack of prior engagement with the topic, concerns about side effects, and uncertainty regarding the scientific evidence.
Despite these challenges, the survey found strong patient interest in innovative prevention methods. Approximately 75% of participants initially considered involvement in a preventive mRNA cancer vaccine study, with this number increasing to roughly 80% following further details. Over 92% said they would want such a vaccine if it were approved in the future.
This enthusiasm contrasts with the underutilization of aspirin, highlighting a paradox in patient behavior. These results show just how great the interest is among those affected in innovative prevention options and in actively participating in research,
Reents said. The study’s collaborative design—integrating patient perspectives from the outset—offers a model for improving engagement and adherence.
Pathways to Improved Prevention Strategies
The LYNX study’s authors emphasize that closing the gap between research and practice requires targeted education and personalized risk-benefit discussions. This network enabled access to numerous affected individuals, allowing research queries and outcomes to be framed through the patients’ viewpoint. By contextualizing research from the patients’ perspective, the study demonstrates how partnerships can drive meaningful change.
As lower-dose aspirin data becomes more widely available, clinicians may need to revisit counseling approaches. The findings also underscore the importance of addressing patient concerns proactively. The project is thus a very good example of research that is conducted not just about, but together with, those affected,
Hüneburg said. With 97% of participants familiar with screening guidelines, the focus now shifts to translating knowledge into action.